New laser aims to sharpen vision for the farsighted

NCT ID NCT05264623

Ongoing Symptom relief Sponsor: Bausch & Lomb Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the safety and effectiveness of the TENEO 317 excimer laser used in LASIK surgery to treat farsightedness (hyperopia) with or without astigmatism. About 140 adults aged 22 and older will receive the laser treatment in one or both eyes and be followed for 12 months. The main goals are to see if vision improves to 20/40 or better without glasses and if the prescription correction is accurate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TENEO 317 Model 2 excimer laser (device)
What this could lead to: If successful, this laser could offer a safe and effective option for LASIK surgery to correct farsightedness and astigmatism.
What could go wrong: This is a single-arm, non-randomized study with no comparison group, so results may not apply broadly. Risks include typical LASIK complications like dry eyes or vision issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPEROPIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPEROPIA

Contacts and locations

Locations

Site 101

Bloomington, Minnesota, 55420, United States
Site 102

Amherst, New York, 14228, United States
Site 103

Omaha, Nebraska, 68118, United States
Site 104

Saint Louis Park, Minnesota, 55416, United States
Site 106

Cedar Park, Texas, 78613, United States
Site 108

Sioux Falls, South Dakota, 57108, United States
Site 111

Fort Myers, Florida, 33912, United States
Site 112

Pittsburgh, Pennsylvania, 15213, United States
Site 113

Newport Beach, California, 92660, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.